OPGN (OpGen, Inc.) חוב לטווח קצר להון

The development of digital systems for the rapid analysis of drug resistance provides OpGen, Inc. (OPGN) with moderate profit, while new licensing contracts are expected in the future. The market trend for the share price, where the indicator is 0.00, correlates with the need of hospitals for the diagnosis of resistant strains and the search for investments to cover operating losses. The business relies on the strong patent protection of the Acuitas platform and lobbying to overcome strict FDA oversight.

For a fundamental valuation of OpGen, Inc. (OPGN), analyzing the ratio of short-term liabilities to equity is critical, as the trend of short-term liabilities relative to equity reflects the company's dependence on quick loans and the risk of cash flow gaps, which is particularly significant for a business in an operational restructuring phase striving to maintain stability while fighting for market share.